治疗性癌症疫苗在前列腺癌的免疫治疗中实现了承诺。
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
机构信息
Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 8B09 MSC 1750, Bethesda, MD 20892, USA.
出版信息
Immunotherapy. 2011 Jan;3(1):27-31. doi: 10.2217/imt.10.77.
Abstract
For many years, preclinical and clinical studies have attempted to harness the power of the immune system and focus it on malignant cells in an attempt to improve clinical outcomes for patients with cancer. This paper describes the landmark Phase III trial that led to the first US FDA approval of a therapeutic cancer vaccine. In a randomized trial of 512 patients, those treated with sipuleucel-T survived for 25.8 months compared with those treated with placebo, who survived 21.7 months (HR: 0.78; p = 0.03). There was, however, no change in time to progression, which may relate to the underlying mechanism of this new class of therapeutics.
摘要
多年来，临床前和临床研究一直试图利用免疫系统的力量，将其集中在恶性细胞上，以改善癌症患者的临床结果。本文描述了一项具有里程碑意义的 III 期临床试验，该试验导致了首个美国 FDA 批准的治疗性癌症疫苗。在一项 512 名患者的随机试验中，接受 sipuleucel-T 治疗的患者存活时间为 25.8 个月，而接受安慰剂治疗的患者存活时间为 21.7 个月（HR：0.78；p = 0.03）。然而，无进展时间没有变化，这可能与这一新类治疗药物的潜在机制有关。
相似文献
1
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
Immunotherapy. 2011 Jan;3(1):27-31. doi: 10.2217/imt.10.77.
2
Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D. 2006;7(3):197-201. doi: 10.2165/00126839-200607030-00006.
3
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
BJU Int. 2012 Jul;110(2 Pt 2):E99-104. doi: 10.1111/j.1464-410X.2011.10790.x. Epub 2011 Dec 16.
4
Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
Ann Pharmacother. 2008 Jan;42(1):91-8. doi: 10.1345/aph.1K429. Epub 2007 Dec 19.
5
Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs. 2003;17(1):69-72. doi: 10.2165/00063030-200317010-00007.
6
Cancer immunotherapy: sipuleucel-T and beyond.
Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813.
7
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design.
Cancers (Basel). 2020 Oct 10;12(10):2908. doi: 10.3390/cancers12102908.
8
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Expert Rev Vaccines. 2011 Feb;10(2):141-50. doi: 10.1586/erv.10.173.
9
Immune-based therapies for metastatic prostate cancer: an update.
Immunotherapy. 2018 Feb 1;10(4):283-298. doi: 10.2217/imt-2017-0123.
10
Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Expert Rev Vaccines. 2015;14(12):1529-41. doi: 10.1586/14760584.2015.1099437. Epub 2015 Oct 21.
引用本文的文献
1
Highlights into historical and current immune interventions for cancer.
Int Immunopharmacol. 2023 Apr;117:109882. doi: 10.1016/j.intimp.2023.109882. Epub 2023 Feb 27.
2
Emerging Trends in Immunotherapy for Cancer.
Diseases. 2022 Sep 6;10(3):60. doi: 10.3390/diseases10030060.
3
Unleashing the therapeutic potential of human kallikrein-related serine proteases.
Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi: 10.1038/nrd4534. Epub 2015 Feb 20.
4
Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide.
Cancer Immunol Immunother. 2015 Apr;64(4):447-57. doi: 10.1007/s00262-015-1654-z. Epub 2015 Jan 13.
5
CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.
J Virol. 2011 Jul;85(14):7216-24. doi: 10.1128/JVI.00543-11. Epub 2011 May 18.
本文引用的文献
1
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.
2
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
3
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
4
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol Immunother. 2010 May;59(5):663-74. doi: 10.1007/s00262-009-0782-8. Epub 2009 Nov 5.
5
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.
6
The anticancer immune response: indispensable for therapeutic success?
J Clin Invest. 2008 Jun;118(6):1991-2001. doi: 10.1172/JCI35180.
7
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Clin Cancer Res. 2008 Jun 1;14(11):3536-44. doi: 10.1158/1078-0432.CCR-07-4025.
8
Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
Ann Pharmacother. 2008 Jan;42(1):91-8. doi: 10.1345/aph.1K429. Epub 2007 Dec 19.
9
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
Front Biosci. 2007 Sep 1;12:4957-71. doi: 10.2741/2441.
10
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol. 2006 Jul 1;24(19):3089-94. doi: 10.1200/JCO.2005.04.5252.
Zotero 插件